Ionis Pharmaceuticals, Inc. (IONS)
58.09
-0.04
(-0.07%)
USD |
NASDAQ |
Sep 04, 16:00
51.90
-6.19
(-10.66%)
After-Hours: 20:00
Ionis Pharmaceuticals SG&A Expense (TTM) : 527.56M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 527.56M |
| March 31, 2026 | 467.79M |
| December 31, 2025 | 393.68M |
| September 30, 2025 | 351.68M |
| June 30, 2025 | 316.51M |
| March 31, 2025 | 291.00M |
| December 31, 2024 | 267.40M |
| September 30, 2024 | 250.40M |
| June 30, 2024 | 258.71M |
| March 31, 2024 | 239.74M |
| December 31, 2023 | 232.61M |
| September 30, 2023 | 209.61M |
| June 30, 2023 | 174.07M |
| March 31, 2023 | 161.73M |
| December 31, 2022 | 150.34M |
| September 30, 2022 | 140.34M |
| June 30, 2022 | 137.02M |
| March 31, 2022 | 159.68M |
| December 31, 2021 | 186.75M |
| September 30, 2021 | 287.75M |
| June 30, 2021 | 325.10M |
| March 31, 2021 | 340.66M |
| December 31, 2020 | 354.46M |
| September 30, 2020 | 298.73M |
| June 30, 2020 | 290.32M |
| Date | Value |
|---|---|
| March 31, 2020 | 293.42M |
| December 31, 2019 | 286.64M |
| September 30, 2019 | 270.47M |
| June 30, 2019 | 279.15M |
| March 31, 2019 | 270.23M |
| December 31, 2018 | 245.67M |
| September 30, 2018 | 224.27M |
| June 30, 2018 | 182.34M |
| March 31, 2018 | 138.46M |
| December 31, 2017 | 108.49M |
| September 30, 2017 | 80.82M |
| June 30, 2017 | 64.22M |
| March 31, 2017 | 51.73M |
| December 31, 2016 | 48.62M |
| September 30, 2016 | 43.76M |
| June 30, 2016 | 42.32M |
| March 31, 2016 | 40.27M |
| December 31, 2015 | 37.17M |
| September 30, 2015 | 30.82M |
| June 30, 2015 | 26.54M |
| March 31, 2015 | 23.23M |
| December 31, 2014 | 20.14M |
| September 30, 2014 | 17.99M |
| June 30, 2014 | 16.95M |
| March 31, 2014 | 15.88M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 1.318B |
| Biogen, Inc. | 2.594B |
| BridgeBio Pharma, Inc. | 645.86M |
| Vertex Pharmaceuticals, Inc. | 2.008B |
| Arrowhead Pharmaceuticals, Inc. | 172.57M |